Unibest
← Back to patent-cliff list

Difamilast

Tier C — Watch / trade

Difamilast

Otsuka Holdings Co Ltd
Originator
2021
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:PDE4

Brand:モイゼルト, Moizerto

Indications (approved):Atopic dermatitis

Regional status

US
Approved
2026-02-12
EU
No progress
2014-06-20
China
Filed / under review
2025-09-25
Japan
Approved
2021-09-27

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 10 · Total yield 18.58 g
DIFAM-001177429-27-5DIFAM-00293652-48-3DIFAM-0031574285-26-9DIFAM-00470-23-5DIFAM-0051574285-28-1DIFAM-0061574285-30-5DIFAM-0071574285-32-7DIFAM-0081574285-36-1DIFAM-0091574285-38-3DIFAM-0101074-82-4DIFAM-0111574285-40-7DIFAM-0121574285-43-0DIFAM-013134-11-2Difamilast937782-05-3API · Difamilast
CodeCAS No.Intermediate
DIFAM-001177429-27-5ethyl 4-(benzyloxy)-3-hydroxybenzoate
DIFAM-00293652-48-34-(benzyloxy)-3-isopropoxybenzoic acid
DIFAM-0031574285-26-94-(benzyloxy)-3-isopropoxybenzamide
DIFAM-00470-23-5ethyl 3-bromo-2-oxopropanoate
DIFAM-0051574285-28-1ethyl 2-(4-(benzyloxy)-3-isopropoxyphenyl)oxazole-4-carboxylate
DIFAM-0061574285-30-5ethyl 2-(4-hydroxy-3-isopropoxyphenyl)oxazole-4-carboxylate
DIFAM-0071574285-32-7ethyl 2-(4-(difluoromethoxy)-3-isopropoxyphenyl)oxazole-4-carboxylate
DIFAM-0081574285-36-1(2-(4-(difluoromethoxy)-3-isopropoxyphenyl)oxazol-4-yl)methanol
DIFAM-0091574285-38-34-(bromomethyl)-2-(4-(difluoromethoxy)-3-isopropoxyphenyl)oxazole
DIFAM-0101074-82-4potassium 1,3-dioxoisoindolin-2-ide
DIFAM-0111574285-40-72-((2-(4-(difluoromethoxy)-3-isopropoxyphenyl)oxazol-4-yl)methyl)isoindoline-1,3-dione
DIFAM-0121574285-43-0(2-(4-(difluoromethoxy)-3-isopropoxyphenyl)oxazol-4-yl)methanamine hydrochloride
DIFAM-013134-11-22-ethoxybenzoic acid
Difamilast937782-05-3N-((2-(4-(difluoromethoxy)-3-isopropoxyphenyl)oxazol-4-yl)methyl)-2-ethoxybenzamide

Frequently asked questions

What are the approved indications of Difamilast?

Approved indications include: Atopic dermatitis.

When does the Difamilast patent expire?

No public expiry year is available for Difamilast yet; this page updates once verified.

How many synthesis routes are recorded for Difamilast?

1 synthesis routes are recorded; the shortest is 10 steps with 18.58 g total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Difamilast intermediates?

All intermediates in Difamilast routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for Difamilast intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27